

CURRICULUM VITAE

Steven J. Becker, D.O.
Collaborative NeuroScience Network, Inc.
South Bay Research Center
19401 S. Vermont Avenue, Suite F-100
Torrance, CA 90502
(310) 523-4200

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Site Liaison
Tel. (866) 669-0234
Fax (208) 575-3169
Email: clinicaltrials@btheodore.com

AFFILIATION:

Collaborative Neuroscience Network, Inc.
Garden Grove, CA

Katella Wellness Center, Inc.
Los Alamitos, CA

Pacific Hospital of Long Beach
Long Beach, CA

EDUCATION:

1989 – 1991 Biology Major
University of California, Riverside, CA

1991 - 1994 Bachelor of Science in Biology
Wright State University, Dayton, OH

1994 - 1996 Masters of Science in Anatomy
Wright State University, Dayton, OH

1996 – 2000 Doctor of Osteopathy
Ohio University College of Osteopathic Medicine, Athens, OH

INTERNSHIPS, RESIDENCIES, AND FELLOWSHIPS:

2000 - 2003 Internal Medicine Residency
Pacific Hospital (PHLB), Long Beach, CA

CERTIFICATIONS:

Board Certified in Internal Medicine

LICENSURE:

State of California Medical License (Osteopathic)

PROFESSIONAL EXPERIENCE:

Investigator, Collaborative Neuroscience Network, Inc. 2007 – Present

Internal Medicine Program Director, Pacific Hospital of Long Beach, Long Beach, CA 2004 – Present

Partner, The Katella Wellness Center, Inc., 2005 – Present

Clinical Teaching Supervisor and Director of Inpatient Care for the Residency Program, Pacific Hospital, Long Beach, CA, 2003 – 2004

Teaching Assistant in Undergraduate Microanatomy, Wright State University, Dayton, OH, 1995

Patient Transporter, Grandview Hospital, Dayton, OH 1991 - 1995

INVESTIGATOR EXPERIENCE:

Alzheimer's Disease • Bipolar Disorder • Epilepsy • Major Depressive Disorder

Parkinson's Disease • Schizophrenia

ADDITIONAL TREATMENT EXPERIENCE:

Asthma • Chronic Pain • COPD • Diabetes • Electrolyte Disturbances (Hyperphosphatemia)
High Blood Pressure • Hypertension • Hyperlipidemia • Menopausal/Women's health • Obesity
Osteoarthritis • Osteoporosis • Renal Failure • Schizophrenia • Smoking Cessation • Vaccines

CLINICAL TRIAL EXPERIENCE:

Alzheimer's Disease

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXX in the Treatment of Patients with Prodromal Alzheimer's Disease

A Phase III, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating XXX in Patients with Mild-to-Moderate Alzheimer's Disease on XXX

CLINICAL TRIAL EXPERIENCE (continued):

A Phase III, Multi-Center, Parallel-Group, Long Term Safety and Tolerability Treatment Trial of XXX in subjects with Alzheimer's Disease who Participated in Study XXX or in Study XXX

A Phase IIb, Nicotinic Agonist Alzheimer's Disease Trial, A Dose-Ranging, Randomized, Double-Blind, Parallel-Group, Placebo-Controller, Multi-Center Study of XXX Used as Add-On to XXX Treatment in Patients with Mild to Moderate Symptoms of Alzheimer's Disease

A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Three Dosage Levels of XXX in Outpatients with Mild to Moderate Alzheimer's Disease Treated with a Cholinesterase Inhibitor

A Multi-Center, Randomized Double-Blind Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of XXX in the Treatment of Patients with Mild to Moderate Alzheimer's Disease

Bipolar Disorder

A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of XXX Adjunctive to XXX or XXX for the Treatment of Bipolar Depression.

A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of XXX for the Treatment of Bipolar I Depression

A 24-Week, Flexible-Dose, Open-Label Extension Study of XXX for the Treatment of Bipolar Depression

A Double-Blind, Placebo-Controlled Study of XXX in Bipolar Depression

Epilepsy

A Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of XXX Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs And Long-Term Extension XXX Study for the XXX Double-Blind Monotherapy study

A Randomized, Double-Blind, Parallel-Group, Multi-center Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of XXX, XXX, and XXX as Adjunctive Therapy in Subjects with Partial Onset Seizures

An International, Double-Blind, Randomized, Multi-center, Parallel Group, Historical-Control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of XXX in Subjects (≥ 16 to 75 years old) with Partial Onset Seizures with or without Secondary Generalization

CLINICAL TRIAL EXPERIENCE (continued):

Major Depressive Disorder

A Double-Blind, Placebo-Controlled Study of XXX as Adjunctive Therapy in Major Depressive Disorder

An Eight-Week, Multi-Center, Randomized, Double-Blind, Placebo-and XXX Controlled Study of the Efficacy, Safety and Tolerability of XXX Given Once Daily in the Treatment of Major Depressive Disorder (MDD) Following a 52-Week Open-Label Treatment with XXX

Parkinson's Disease

A Randomized, Double-Blind, Two-Way Crossover Study to Compare XXX to Standard Carbidopa-Levodopa and Characterization of Multiple-dose Pharmacokinetics and

The Pharmacodynamics of XXX in Levodopa-Experienced Parkinson's Disease Subjects with Motor Complications

A Placebo-Controlled Study To Evaluate The Safety And Efficacy Of XXX in Subjects with Parkinson's Disease

Schizophrenia

A Prospective, Randomized, Active-controlled, Rater-Blinded, International Study of the Prevention of Relapse Comparing XXX to XXX in Adults with Recently-Diagnosed Schizophrenia Who Are at High Risk of Relapse

A Phase II, 6-week, Multi-center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral XXX Once Daily and XXX Once Daily for Treatment of Hospitalized Adult Patients with Acute Schizophrenia & Extension Study, A Phase II, Multicenter, Open-label Study to Assess the Safety and Tolerability of Flexible-dosed Oral XXX as Monotherapy in Adult Patients with Schizophrenia

A Phase III Randomized, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Two Doses of XXX in Acutely Psychotic Subjects with Schizophrenia
A Single-Arm Evaluation of the Safety of XXX in Subjects with Schizophrenia or Schizoaffective Disorder with Hepatic Disease

A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed Dosage of XXX in the Treatment of Subjects with Schizophrenia

MEMBERSHIPS:

Member, American Osteopathic Association

Member, American Medical Association

Member, American College of Osteopathic Internists

AWARDS/HONORS RECEIVED:

Attending Physician: Physician Appreciation Award 2004-05
Faculty Teacher of the Year 2003-04

Residency: Chief Resident Award, 2003
Golden Apple Teaching Award for Outstanding Clinical Teaching, 2003

AWARDS/HONORS RECEIVED (continued):

Medical School: The Family Medicine Department Student of the Year, 1997
President of the OU-COM Chapter of the American College of
Osteopathic Medicine, 1997-1998

Undergraduate: Dean's List 1993-1994